FTC Approves Modified Final Order Addressing Competitive Concerns about Hikma Pharmaceuticals PLC’s Acquisition of Roxane
Date
The Federal Trade Commission has approved a modified final order settling charges that Hikma Pharmaceuticals PLC’s $2 billion acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane...